Flecainide Acetate

氟卡尼醋酸盐

Report date: 2023/06/10 20:00:22
NME

Base Information

Drug NameFlecainide Acetate
Drug Alias NameAlmarytm氟瓜尼氟卡律AristocorFlecainidum +[19] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockers
TargetsSodium channel alpha subunit
Therapy Area/IndicationsPainMyocardial InfarctionCoronary Disease +[12] 
Global Approved IndicationsArrhythmias, Cardiac
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1985/10/31
Country/TerritoryCzechiaBelgiumUnited States +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAlvogen
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of RochesterInCarda Therapeutics Inc
Inactive CompaniesNational Cancer InstituteUniversity Of Wisconsin-MadisonNational Heart, Lung, And Blood Institute (Nhlbi) +[4] 
Active IndicationsCardiomyopathiesAtrial Fibrillation
Inactive IndicationsPainMyocardial InfarctionCoronary Disease +[10] 

Other Information

ATC CodeC01BC04
Related LinksWikipediaDrugBankKEGG